Sihuan Pharmaceutical Holdings Group Crecimiento futuro

Future controles de criterios 5/6

Sihuan Pharmaceutical Holdings Group se prevé un crecimiento anual de los beneficios y los ingresos de 119.4% y 20.9% respectivamente. Se prevé que el BPA sea de grow en 121% al año. Se prevé que la rentabilidad de los fondos propios sea de 4.5% en 3 años.

Información clave

117.7%

Tasa de crecimiento de los beneficios

123.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	12.8%
Tasa de crecimiento de los ingresos	25.5%
Rentabilidad financiera futura	6.7%
Cobertura de analistas	Low
Última actualización	16 Nov 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

SZSC:460 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	3,186	337	N/A	N/A	1
12/31/2024	2,733	107	N/A	N/A	1
12/31/2023	1,861	-54	N/A	N/A	N/A
6/30/2023	1,773	-2,041	-697	-300	N/A
3/31/2023	1,977	-1,996	-620	-127	N/A
12/31/2022	2,181	-1,951	-543	46	N/A
6/30/2022	2,595	-144	-306	425	N/A
3/31/2022	2,817	141	-183	545	N/A
12/31/2021	3,038	427	-60	665	N/A
9/30/2021	3,304	681	63	740	N/A
6/30/2021	3,317	945	187	815	N/A
3/31/2021	2,891	727	-83	521	N/A
12/31/2020	2,464	508	-353	227	N/A
9/30/2020	2,370	-14	-429	214	N/A
6/30/2020	2,275	-537	-504	200	N/A
3/31/2020	2,577	-1,623	162	809	N/A
12/31/2019	2,878	-2,709	828	1,418	N/A
9/30/2019	3,088	-1,927	1,238	1,726	N/A
6/30/2019	3,297	-1,144	1,647	2,033	N/A
3/31/2019	3,107	238	1,525	1,913	N/A
12/31/2018	2,917	1,620	1,403	1,793	N/A
9/30/2018	2,751	1,496	1,481	1,906	N/A
6/30/2018	2,584	1,372	1,559	2,019	N/A
3/31/2018	2,665	1,411	1,495	1,968	N/A
12/31/2017	2,746	1,449	1,431	1,918	N/A
9/30/2017	2,992	1,632	N/A	1,889	N/A
6/30/2017	3,238	1,815	N/A	1,860	N/A
3/31/2017	3,212	1,761	N/A	1,939	N/A
12/31/2016	3,186	1,708	N/A	2,018	N/A
9/30/2016	2,984	1,528	N/A	2,037	N/A
6/30/2016	2,781	1,347	N/A	2,056	N/A
3/31/2016	2,974	1,705	N/A	1,812	N/A
12/31/2015	3,167	2,062	N/A	1,569	N/A
9/30/2015	3,321	2,181	N/A	1,691	N/A
6/30/2015	3,474	2,299	N/A	1,813	N/A
3/31/2015	3,279	1,985	N/A	1,787	N/A
12/31/2014	3,084	1,671	N/A	1,761	N/A
9/30/2014	2,365	1,581	N/A	1,650	N/A
6/30/2014	1,645	1,491	N/A	1,538	N/A
3/31/2014	2,116	1,388	N/A	1,556	N/A
12/31/2013	2,586	1,285	N/A	1,574	N/A
9/30/2013	4,355	1,182	N/A	1,408	N/A
6/30/2013	3,978	1,060	N/A	1,306	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. tasa de ahorro: 460 se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2%).

Beneficios frente mercado: 460 se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: 460 se espera que sea rentable en los próximos 3 años.

Ingresos vs. Mercado: 460Se prevé que los ingresos de la empresa (20.9% al año) crezcan más deprisa que los del mercado Hong Kong (8.2% al año).

Ingresos de alto crecimiento: 460Se prevé que los ingresos de la empresa (20.9% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Futura rentabilidad financiera (ROE): 460Se prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (4.5%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Sihuan Pharmaceutical Holdings Group Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Recent updates

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: HK$2.68

Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement

Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration

New 90-day high: HK$1.32

Upcoming Dividend of HK$0.035 Per Share

Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD)

First half earnings released

Deputy General Manager recently bought HK$19m worth of stock

Earnings released

New 90-day high - HK$1.03

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento